Viridian Therapeutics (GB:0K1R)
UK Market

Viridian Therapeutics Stock Analysis & Ratings

GB:0K1R Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$13.99
Average Volume (3M)41.00
Market Cap$390.70M
P/E Ratio-1.8
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-7.69



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Viridian Therapeutics’s market cap?
    Viridian Therapeutics’s market cap is $390.70M.
      What is Viridian Therapeutics’s price target?
      The average price target for Viridian Therapeutics is $33.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $40.00 ,the lowest forecast is $31.00. The average price target represents 138.74% Increase from the current price of $13.99.
        What do analysts say about Viridian Therapeutics?
        Viridian Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Viridian Therapeutics’s upcoming earnings report date?
          Viridian Therapeutics’s upcoming earnings report date is Aug 10, 2022 which is in 81 days.
            How were Viridian Therapeutics’s earnings last quarter?
            Viridian Therapeutics released its earnings results on May 12, 2022. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.975 by -$0.005.
              Is Viridian Therapeutics overvalued?
              According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
                Does Viridian Therapeutics pay dividends?
                Viridian Therapeutics does not currently pay dividends.
                What is Viridian Therapeutics’s EPS estimate?
                Viridian Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Viridian Therapeutics have?
                Viridian Therapeutics has 27,930,000 shares outstanding.
                  What happened to Viridian Therapeutics’s price movement after its last earnings report?
                  Viridian Therapeutics reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.975. Following the earnings report the stock price went up 2.416%.
                    Which hedge fund is a major shareholder of Viridian Therapeutics?
                    Among the largest hedge funds holding Viridian Therapeutics’s share is Perceptive Advisors LLC. It holds Viridian Therapeutics’s shares valued at 26M.


                      Viridian Therapeutics Stock Analysis

                      The Viridian Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Viridian Therapeutics

                      Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

                      Similar Stocks
                      Price & Change
                      Enzo Biochem
                      Cardiff Oncology

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis